OMNIAB, INC. (OABI) Operating Margin
- Operating margin · 12 months: Value -125.78%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -125.78% | Operating income / revenue. Period ending 2026-06-30. $-48.37M ÷ $38.46M × 100 ≈ -125.78% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -48.37M USD | Operating Income (Loss) |
| Revenue | 38.46M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 43.51M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-48.37M | $38.46M | (m) | $43.51M | (m) | -125.78% |
| 2026-03-31 | $-57.95M | $28.94M | (m) | $44.79M | (m) | -200.26% |
| 2025-12-31 | $-68.97M | $18.67M | (m) | $47.75M | (m) | -369.49% |
| 2025-09-30 | $-69.08M | $21.09M | (m) | $47.15M | (m) | -327.50% |
| 2025-06-30 | $-70.71M | $23.03M | (m) | $50.09M | (m) | -307.06% |
| 2025-03-31 | $-70.79M | $26.74M | (m) | $53.16M | (m) | -264.71% |
| 2024-12-31 | $-74.50M | $26.39M | (m) | $55.11M | (m) | -282.30% |
| 2024-09-30 | $-79.83M | $20.41M | (m) | $56.57M | (m) | -391.14% |
| 2024-06-30 | $-80.38M | $21.71M | (m) | $57.12M | (m) | -370.17% |
| 2024-03-31 | $-83.52M | $21.05M | (m) | $57.32M | (m) | -396.84% |
| 2023-12-31 | $-69.42M | $34.16M | (m) | $56.52M | (m) | -203.19% |
| 2023-09-30 | $-39.16M | $64.69M | (m) | $54.68M | (m) | -60.54% |
| 2023-06-30 | $-33.76M | $66.12M | (m) | $54.00M | (m) | -51.05% |
| 2023-03-31 | $-26.88M | $66.37M | (m) | $51.35M | (m) | -40.50% |
| 2022-12-31 | $-26.65M | $59.08M | (m) | $48.36M | (m) | -45.11% |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-35.61M | $34.75M | (m) | $39.23M | (m) | -102.48% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |